Clinical Trials Browser

Phase 2 × Neoplasm Metastasis × Panitumumab × Clear all

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05638295 2026-03-17

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Phase 2 Recruiting

105 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT00819780 2022-12-06

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Phase 2 Completed

285 enrolled 31 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00089635 2022-11-07

Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

Phase 2 Completed

203 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT00446446 2022-10-05

PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

Phase 2 Completed

52 enrolled 17 charts

Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03142516 2021-06-21

OPALO

Phase 2 Completed

20 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

50 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT00418938 2018-10-17

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Phase 2 Completed

266 enrolled 17 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00454779 2018-10-17

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Phase 2 Completed

113 enrolled 18 charts

Neoplasm Metastasis, Recurrence

NCT00411450 2016-02-15

PRECEPT

Phase 2 Completed

116 enrolled 20 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00083616 2014-01-10

Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

Phase 2 Completed

185 enrolled 15 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00111774 2013-05-14

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

Phase 2 Completed

150 enrolled

Gastrointestinal

Carcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00950820 2013-03-04

VOXEL

Phase 2 Terminated

9 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT00113776 2011-01-21

Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer

Phase 2 Completed

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00101920 2010-10-15

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Completed

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00346099 2008-01-07

Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00034346 2007-12-24

ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Completed

194 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms